Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.
about
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaImpact of involuntary out-patient commitment on reducing hospital services: 2-year follow-upFactors associated with medication adherence among patients with schizophrenia in Mekelle, Northern EthiopiaEffect of a Multi-Dimensional and Inter-Sectoral Intervention on the Adherence of Psychiatric PatientsAddressing non-adherence to antipsychotic medication: a harm-reduction approach.Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Definitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewDrug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophreniaDepot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort StudySafety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Religious affiliation as a predictor of involuntary psychiatric admission: a brazilian 1-year follow-up study.Schizophrenia: overview and treatment options.The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophreniaThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Prevalence and socio-demographic risk factors associated with psychoactive substance use in psychiatric out-patients of a tertiary hospital in Nigeria.Integrated treatment vs. treatment-as-usual for recent onset schizophrenia; 12 year follow-up on a randomized controlled trial.Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisPatient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophreniaHealth-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.Development of controlled-release matrix tablet of risperidone: influence of Methocel®- and Ethocel®-based novel polymeric blend on in vitro drug release and bioavailabilityEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaStrategies to improve medication adherence in patients with schizophrenia: the role of support services.High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs.Cost-Effectiveness of Financial Incentives to Promote Adherence to Depot Antipsychotic Medication: Economic Evaluation of a Cluster-Randomised Controlled TrialPsychotic relapse and associated factors among patients attending health services in Southwest Ethiopia: a cross-sectional study.Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment RegimensPredictors of long term use of psychiatric services of patients with recent-onset schizophrenia: 12 years follow-up.Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.Mobile.net: Mobile Telephone Text Messages to Encourage Adherence to Medication and to Follow up With People With Psychosis: Methods and Protocol for a Multicenter Randomized Controlled Two-Armed Trial.A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia.Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.Risperidone nonadherence and return of positive symptoms in the early course of schizophreniaDenial and acceptance coping styles and medication adherence in schizophrenia.Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study.Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.
P2860
Q24597701-72022DBA-7E7E-485F-B4A6-DB180FEB1165Q26772275-A9D1DF98-969A-4F22-AC3B-68E5C556C9EDQ28545127-2E95E890-1FAE-4B43-8F01-4AD1DD596A16Q28550045-26CC381E-77A8-4959-8BDC-7A664C13C805Q30409210-F33B9095-A405-4BDF-A7E8-79EF6698D1FFQ30937746-E94545EE-E350-4104-A52C-D0DCF4102631Q33589087-512D8814-0E2F-42C4-834C-ACD98688453FQ33650097-77AB4140-8BCC-41FC-B1F0-F6E0B7DA3308Q33816366-998DDBD4-176A-4BC1-85A3-961F677D747BQ33834476-F6FDD400-8964-4DF8-AC6A-F4FBA043BC6DQ33878816-FD6E483C-C222-4450-AE99-0EBCA27DDBE9Q34023154-E0CC1D01-5542-47D1-B5A4-C9588D8713CFQ34154951-EEE3B54C-AFC9-4BD2-A1A7-BDECD5666F1CQ34254832-2CD3FFAB-FD5E-4B07-9E4D-812B79D5037AQ34418847-FC8C0CBD-8E87-487C-9B84-9DED3B36FA7EQ34675579-81184F69-413F-4214-8D39-4CA8F26DA130Q34880990-2712C490-F16F-4EDE-8AEA-13B3DC6166DFQ34982167-03B3867E-9288-4771-AA50-931E1BE4A584Q35019258-5A5F1F73-0B26-4528-B507-211B67E330D2Q35100117-97C2DC79-C3C6-438A-A532-C7832C429DB8Q35100385-58BD29F3-9D04-4496-A8F9-04156592933CQ35186007-8B8EE861-5E73-4B25-97AA-9235D2AF07BBQ35507000-3D8BFAD4-647A-411D-846A-C005EFDB89BFQ35605892-21EE207E-7392-4736-9150-4EDCDAF1AEB4Q35882300-17FF1B0D-8D68-4B66-9726-EAC7A642A6EEQ36035382-4AA064DF-6FA8-4E49-84E2-19B6DD3142A5Q36044794-5B703558-4EB6-448C-8131-30EC0A303280Q36137208-8D6474B6-E318-4C08-ADBF-EA8BD6ABEE98Q36169820-F4AA07BB-E49E-4392-A97B-67E4E2DE5980Q36198389-318F90EE-8EEE-442A-88AE-FF7C9EDAB60DQ36206941-B728265B-0F8B-4AC7-9DE0-FA6E5C017E72Q36249889-E06D7702-CE72-440A-9A68-45C8C4C5EA0DQ36489412-68173F76-3E98-42E3-8002-5089811BECAEQ36765328-0B1F5F95-9971-4B52-9F8F-E3670EAC680AQ37083505-0566D8B4-20CD-42D9-BC05-A4EBD1588B27Q37248065-3243D98A-CB7E-49F1-A24A-211B9EBB2765Q37348503-0D50AB9E-5B38-48EE-B0B6-D27452B98DC8Q37353847-84C941C1-7EAA-48CC-A557-27F7834BB0FAQ37425737-5BE4A33F-1A2D-4100-80AE-5517A47AA011Q37441407-CD3F3CA7-63A6-4D9B-B850-18494A00A726
P2860
Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Non-adherence to antipsychotic ...... in recent-onset schizophrenia.
@ast
Non-adherence to antipsychotic ...... in recent-onset schizophrenia.
@en
type
label
Non-adherence to antipsychotic ...... in recent-onset schizophrenia.
@ast
Non-adherence to antipsychotic ...... in recent-onset schizophrenia.
@en
prefLabel
Non-adherence to antipsychotic ...... in recent-onset schizophrenia.
@ast
Non-adherence to antipsychotic ...... in recent-onset schizophrenia.
@en
P2860
P356
P1433
P1476
Non-adherence to antipsychotic ...... in recent-onset schizophrenia.
@en
P2093
Jan H Widen
Rolf W Grawe
P2860
P2888
P356
10.1186/1471-244X-8-32
P577
2008-04-30T00:00:00Z
P5875
P6179
1008096995